Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.

Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic ...

Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline ...

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

LUND, SE / ACCESS Newswire / January 9, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today ...

Breast cancer can spread—or metastasize—to many different parts of the body, but it's not well understood why tumors grow better in some organs than others.

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...

The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

Fortunately, eight days after surgery, I received the pathology report and was elated to read that it was an oncocytoma ...